DNTH | Dianthus Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	21.20 - 22.52
52 Week Range	16.39 - 33.77
Beta	1.10
Implied Volatility	110.92%
IV Rank	13.77%
Day's Volume	66,893
Average Volume	264,175
Shares Outstanding	29,597,000
Market Cap	664,748,620
Sector	Healthcare
Industry	Biotechnology
IPO Date	2018-06-21

Valuation
Profitability
Growth
Health
P/E Ratio	3.11
Forward P/E Ratio	N/A
EPS	7.22
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	53
Country	USA
Website	DNTH

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

*Chart delayed

Analyzing fundamentals for DNTH we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see DNTH Fundamentals page.

Watching at DNTH technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DNTH Technicals page.